STOCK TITAN
  1. Home
  2. News
  3. KYMR

Kymera Therapeutics Inc - KYMR STOCK NEWS

Welcome to our dedicated news page for Kymera Therapeutics (Ticker: KYMR), a resource for investors and traders seeking the latest updates and insights on Kymera Therapeutics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Kymera Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Kymera Therapeutics's position in the market.

News
R&D Day Highlights Kymera’s Immunology Strategy and Emerging Pipeline of Novel, First-in-Class Oral Degraders Addressing Multiple Highly Prevalent Immuno-inflammatory Diseases
Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) to advance first-in-class oral degraders with biologics-like activity targeting STAT6, TYK2, and IRAK4. KT-621 expected to enter Phase 1 clinical trial in 2H 2024, KT-294 in 1H 2025, and KT-474 to complete enrollment in both Phase 2 HS and AD studies in 4Q 2024, with topline data expected in 1H 2025. Company to hold virtual Immunology R&D Day webcast on Jan 4, 2024, to share overview of strategy and new programs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
18.86%
Tags
acquisition
-
News
Kymera Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024
Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) to present at the 42nd Annual J.P. Morgan Healthcare Conference. Founder, President, and CEO Nello Mainolfi, Ph.D., will provide an overview of the Company's progress and anticipated milestones for 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
conferences
-
News
Kymera Therapeutics to Host Virtual Immunology R&D Day on January 4
Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) will host a virtual Immunology R&D Day on January 4, 2024, to provide an update on its emerging pipeline of high-value immunology programs, new target disclosures, preclinical data, and clinical study initiation timing.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.33%
Tags
conferences
News
Kymera Therapeutics Presents Interim Results from STAT3 Degrader Phase 1 Clinical Trial at American Society of Hematology Annual Meeting
Rhea-AI Summary
Kymera Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: KYMR), shared new data from its ongoing KT-333 Phase 1 trial. KT-333, a first-in-class STAT3 degrader, demonstrated early signs of antitumor activity across liquid and solid tumors, with major responses in cutaneous T-cell lymphoma and Hodgkin's lymphoma. The drug was well-tolerated, showing robust STAT3 knockdown and positive immunomodulatory effects. The Phase 1 trial is evaluating the safety, tolerability, and clinical activity of KT-333 in adult patients with relapsed and/or refractory lymphomas, leukemias, and solid tumors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.26%
Tags
clinical trial
-
News
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Atopic Dermatitis Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating a $15 Million Payment from Sanofi
Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) has announced the initiation of the randomized Phase 2 clinical trial (ADVANTA) evaluating KT-474 (SAR444656) in Atopic Dermatitis (AD), generating a $15 million milestone payment under its collaboration with Sanofi. The trial is projected to be completed in the first quarter of 2025, with topline Phase 2 data from both the AD and Hidradenitis Suppurativa (HS) trials expected in the first half of 2025. Sanofi is conducting Phase 2 KT-474 studies in both AD and HS, and dosed the first HS patient in October 2023, generating a $40 million milestone payment under the terms of the collaboration.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.2%
Tags
clinical trial
-
News
Kymera Therapeutics Announces Publication of Phase 1 Trial Results for KT-474 (SAR444656), a First-in-Class IRAK4 Degrader, in Nature Medicine
Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced positive Phase 1 clinical trial results for KT-474 (SAR444656), a potent IRAK4 degrader, published in Nature Medicine. The trial demonstrated robust target degradation and pathway inhibition, with a favorable safety profile, encouraging impact on disease burden and symptoms in Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD), and a systemic anti-inflammatory effect in patients. KT-474's unique potential in treating inflammatory diseases was highlighted, with promising Phase 2 clinical trials conducted by Sanofi. The publication also included preclinical data and chemical structure details of KT-474.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.17%
Tags
clinical trial
News
Kymera Therapeutics to Present New Clinical Data from the Phase 1 Trial of STAT3 Degrader KT-333 at the ASH Annual Meeting
Rhea-AI Summary
Kymera Therapeutics, Inc. (NASDAQ: KYMR) announced the release of new Phase 1 data for their KT-333 drug at the ASH 65th Annual Meeting and Exposition. The data includes safety, pharmacokinetics, pharmacodynamics, and clinical responses. The abstract reported positive results, including a partial response in a CTCL patient and stable disease in three solid tumor patients. No dose limiting toxicities or serious adverse events were reported. The presentation will also include preclinical data supporting the potential of STAT3 protein degraders in venetoclax-resistant Acute Myeloid Leukemia.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
conferences clinical trial
-
News
Kymera Therapeutics Announces Third Quarter 2023 Financial Results and Provides a Business Update
Rhea-AI Summary
Kymera Therapeutics reported financial results for Q3 2023 and provided updates on its protein degraders pipeline. The company achieved a $40 million milestone payment from Sanofi for the initiation of Phase 2 trials of KT-474/SAR444656. The Phase 2 trial for KT-474 in atopic dermatitis is expected to begin in Q4 2023. KT-333 (STAT3) showed signs of anti-tumor activity in liquid and solid tumor types. KT-253 (MDM2) achieved clinical proof-of-mechanism and demonstrated anti-tumor activity in solid tumor patients. Development of KT-413 (IRAKIMiD) will be discontinued. Kymera will focus on its immunology pipeline and will hold a virtual Immunology R&D Day on January 4, 2024. The company has a cash balance of $435 million, providing a runway into H1 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.59%
Tags
earnings
-
News
Kymera Therapeutics to Participate in Upcoming November Investor Conferences
Rhea-AI Summary
Kymera Therapeutics, Inc. will participate in several upcoming investor events, including TD Cowen 7th Annual Virtual Fall Oncology Innovation Summit, UBS Biopharma Conference, Stifel 2023 Healthcare Conference, Piper Sandler 35th Annual Healthcare Conference, and Evercore ISI 6th Annual HealthCONx Conference. Live webcasts and replays of the fireside chats will be available on the company's website. The company will also host one-on-one meetings at the J.P. Morgan Equity Opportunities Forum and the Truist Securities BioPharma Symposium.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.03%
Tags
conferences
News
Kymera Therapeutics Announces First Patient Dosed in Phase 2 Hidradenitis Suppurativa Clinical Trial of KT-474 (SAR444656), a First-in-Class, Investigational IRAK4 Degrader, Generating $40 Million Payment from Sanofi
Rhea-AI Summary
Kymera Therapeutics has announced the dosing of the first patient in a Phase 2 clinical trial for hidradenitis suppurativa (HS) using their investigational IRAK4 degrader, KT-474. The trial will evaluate the efficacy and safety of KT-474 compared to placebo in adult patients with moderate to severe HS. The initiation of dosing in this trial has generated a milestone payment of $40 million for Kymera.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.69%
Tags
clinical trial
Stock KYMR logo
Kymera Therapeutics Inc

Nasdaq:KYMR

KYMR Rankings

#1827 Ranked by Market Cap
#4998 Ranked by Stock Gains
N/A Ranked by Dividends

KYMR Stock Data

2.17B
40.08M
1.38%
102.77%
14.83%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Watertown

About KYMR

kymera therapeutics is pioneering a transformative new approach to treating previously untreatable diseases. we are advancing the field of targeted protein degradation, accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. powered by a proprietary predictive modeling capability and a game-changing integrated degradation platform with a novel small molecule modality, our company is committed to accelerating drug discovery with an unmatched ability to target and degrade the most intractable of proteins, and advance new treatment options for patients. learn more at kymeratx.com.